Technology
100 Most Popular
Most Popular Under $25

Viking Therapeutics

$8.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (2.40%) Today
-$0.04 (-0.53%) After Hours

Why Robinhood?

You can buy or sell VKTX and other stocks, options, ETFs, and crypto commission-free!

About

Viking Therapeutics, Inc. Common Stock, also called Viking Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. Read More The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Employees
15
Headquarters
San Diego, California
Founded
2012
Market Cap
615.12M
Price-Earnings Ratio
Dividend Yield
Average Volume
3.69M
High Today
$8.55
Low Today
$8.32
Open Price
$8.40
Volume
575.92K
52 Week High
$24.00
52 Week Low
$4.86

Collections

Technology
100 Most Popular
Most Popular Under $25
Health
Biotechnology
Medical
Therapy
Biopharmaceutical

News

Yahoo FinanceMay 9

Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?

We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. While not all of these picks will be winners, our research shows that these picks historically outperformed the market when we factor in known risk factors. Viking Therapeu...

5,914
Seeking AlphaMay 2

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2019 Results - Earnings Call Transcript

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2019 Earnings Conference Call May 2, 2019 4:30 PM ET Company Participants Stephanie Diaz - Investor Relations Brian Lian - President & Chief Executive Officer Michael Morneau - Vice President of Finance & Administration Conference Call Participants Fang-Ke Huang - SunTrust Robinson Humphrey Timur Ivannikov - Raymond James David Bautz - Zacks Investment Research Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Mayank Mamtani - B. Riley FBR Operato...

4,578
PR NewswireApr 30

Viking Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, April 30, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences. Details of the company's participation are as follows: 5 th Annual SunTrust Robinson Humphrey Life Sciences Summit Details: Viking management will participate in 1-on-1 meetings Date: May 8, 2019 Loc...

2,882

Earnings

-$0.22
-$0.17
-$0.12
-$0.07
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.